dates glp 1 A timeline of GLP- discovery and clinical development. Created in GLP-1 Drugs for Weight Loss

Medical Supervision Requirements: Legitimate programs require healthcare provider evaluation before initiating therapy and ongoing medical oversight throughout treatment

To realize the full potential of GLP-1s, we need digital health

The findings were compelling, tirzepatide not only achieved greater reductions in HbA1c but also delivered significant body weight loss, all while showing a lower incidence of hypoglycemia at the 52-week mark

Over time, pharmacological engineering enabled: Short-acting injectables (e.g., exenatide) Long-acting once-weekly injectables (liraglutide, semaglutide) Multi-target incretin therapies (tirzepatide) Oral peptide formulations and now oral small molecules The most recent breakthrough is the development of orally available GLP-1 receptor agonists, including: Orforglipron (Lilly) Elecoglipron (AstraZeneca) These compounds eliminate the need for injection and could dramatically expand accessibility and adherence in obesity and diabetes populations

Effect of astaxanthin on physical activity factors, lipid profile, inflammatory markers, and antioxidants indices in athletic men: A systematic review and meta-analysis